Tevogen Extends Patel Family Credit Line Through 2029, With $28.6 Million Remaining

What happened

Tevogen amended its unsecured credit line with the Patel Family, allowing borrowing requests through May 31, 2029, with up to $28.6 million available for post-amendment borrowing. The agreement sets $7.40 per share for stock used to repay principal and interest. Tevogen also repaid its existing $7.4 million principal and $177,880 accrued interest in shares on November 2, 2026.

Confirmed

Global impact / market context

The amendment could give Tevogen financing flexibility if it draws the available funds, potentially helping cover company costs without an immediate cash repayment. But borrowing creates repayment obligations, while settling debt with shares can increase the share count and reduce existing investors’ ownership percentage.

Analyst inference

The $28.6 million is available credit, not cash already received. If Tevogen borrows, the funds could support spending or operations, but repayment would remain due; each borrowing may last up to 48 months. Share repayment terms tie debt settlement to issuing stock at $7.40 per share.

Analyst inference

What to watch

1. Watch whether Tevogen requests any of the available credit: a draw would provide company funds for costs or spending, while adding repayment obligations under the amended agreement. Analyst inference
2. Check future disclosures for shares issued to repay principal or interest at $7.40 per share, because these issuances would increase the share count and dilute existing ownership. Analyst inference
3. Tevogen repaid $7.4 million of principal and $177,880 of accrued interest in shares on November 2, 2026, eliminating outstanding liabilities under the agreement. Confirmed

Evidence

• Original source link unavailable